Prolonged Persistence of Lamivudine-resistant Mutant and Emergence of New Lamivudine-resistant Mutants Two Years After Lamivudine Withdrawal in HBsAg-positive Chronic Hepatitis Patient: A Case Report

[1]  M. Nakanishi,et al.  Long‐term follow‐up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region , 2005, Journal of viral hepatitis.

[2]  S. Fan,et al.  Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. , 2003, Journal of hepatology.

[3]  Y. Liaw,et al.  The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. , 2003, Journal of hepatology.

[4]  D. Vassilopoulos,et al.  Treatment of HBeAg-negative chronic hepatitis B. , 2003, Seminars in liver disease.

[5]  Yoshiyuki Suzuki,et al.  Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study. , 2003, Journal of hepatology.

[6]  M. Rizzetto,et al.  Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine. , 2003, Journal of hepatology.

[7]  C. Wai,et al.  Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B , 2002, Gut.

[8]  J.-H. Wang,et al.  Fatal Hepatic Failure After Emergence of the Hepatitis B Virus Mutant During Lamivudine Therapy in a Patient with Liver Cirrhosis , 2002, Scandinavian journal of gastroenterology.

[9]  J. Chi,et al.  Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. R. Rebello Pinho,et al.  Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B , 2001, Journal of Gastroenterology.

[11]  T. Liang,et al.  Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. , 2001, Gastroenterology.

[12]  Y. Liaw Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. , 2001, Antiviral chemistry & chemotherapy.

[13]  A. Lok,et al.  Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy , 2000, Hepatology.

[14]  R. D. de Man,et al.  The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. , 1998, Journal of hepatology.

[15]  K. Chayama,et al.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.